Codex Genetics, a leading precision diagnostics provider in Hong Kong, has announced an exclusive collaboration with Pacific Edge, developer of the Cxbladder suite of non-invasive genomic urine tests, to expand access to advanced bladder cancer diagnostics across hospitals and clinics in the region.
Through this partnership, Codex Genetics will offer the full portfolio of clinically validated Cxbladder tests—Detect, Monitor, and Triage—helping urologists and oncologists improve risk stratification and ongoing surveillance of urothelial bladder cancer. These urine-based tests combine genomic biomarker analysis with clinical algorithms to deliver earlier, actionable insights for patient management.
Following an update in February 2025, the American Urological Association (AUA) and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) included Cxbladder Triage in their Microhematuria Guideline. The guideline now recommends urine-based biomarkers to reduce cystoscopy use, with Cxbladder Triage specifically cited and backed by “Grade A” evidence from the STRATA randomized controlled trial.
“Bladder cancer is costly to manage due to its high recurrence and lifelong monitoring needs,” said Dr. Aldrin Yim, co-founder of Codex Genetics. “By offering a reliable, non-invasive alternative that can limit unnecessary cystoscopies, we aim to streamline workflows and focus resources on patients who need them most.”
Dr. Peter Meintjes, CEO of Pacific Edge, added: “Codex’s leadership in precision diagnostics makes them the ideal partner to bring Cxbladder’s benefits to Hong Kong, providing clinicians and patients with a less invasive, clinically proven solution.”
Bladder cancer is the ninth most common cancer globally, with recurrence driving significant clinical and economic burdens. Cxbladder has been used in over 100,000 patients worldwide and is supported by more than 25 peer-reviewed studies showing high sensitivity and strong negative predictive value. Its integration into care pathways can reduce unnecessary invasive procedures and enhance decision-making for both public and private healthcare systems.